Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.
De Giglio A, De Biase D, Favorito V, Maloberti T, Di Federico A, Zacchini F, Venturi G, Parisi C, Gustavo Dall'Olio F, Ricciotti I, Gagliano A, Melotti B, Sperandi F, Altimari A, Gruppioni E, Tallini G, Gelsomino F, Montanaro L, Ardizzoni A. De Giglio A, et al. Among authors: melotti b. Lung Cancer. 2024 Dec 20;199:108058. doi: 10.1016/j.lungcan.2024.108058. Online ahead of print. Lung Cancer. 2024. PMID: 39709652 Free article.
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience.
De Giglio A, Grandinetti V, Aprile M, Borelli G, Campus A, Croci Chiocchini AL, Busutti M, Vischini G, Di Federico A, Sperandi F, Melotti B, Ardizzoni A, La Manna G, Gelsomino F. De Giglio A, et al. Among authors: melotti b. Lung Cancer. 2022 Dec;174:91-96. doi: 10.1016/j.lungcan.2022.10.007. Epub 2022 Nov 2. Lung Cancer. 2022. PMID: 36356493
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.
De Giglio A, Leonetti A, Comito F, Filippini DM, Mollica V, Rihawi K, Peroni M, Mazzaschi G, Ricciotti I, Carosi F, Marchetti A, Rosellini M, Gagliano A, Favorito V, Nobili E, Gelsomino F, Melotti B, Marchese PV, Sperandi F, Di Federico A, Buti S, Perrone F, Massari F, Pantaleo MA, Tiseo M, Ardizzoni A. De Giglio A, et al. Among authors: melotti b. Cancer Immunol Immunother. 2024 Oct 3;73(12):246. doi: 10.1007/s00262-024-03836-w. Cancer Immunol Immunother. 2024. PMID: 39358642 Free PMC article.
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.
Di Federico A, Angelicola S, Frascino M, Siracusa I, Bisanti B, Ruzzi F, Semprini MS, De Jonge H, De Giglio A, Sperandi F, Brocchi S, Melotti B, Giunchi F, Gruppioni E, Altimari A, Lollini PL, Ardizzoni A, Palladini A, Gelsomino F. Di Federico A, et al. Among authors: melotti b. JCO Precis Oncol. 2024 Dec;8:e2400240. doi: 10.1200/PO.24.00240. Epub 2024 Dec 5. JCO Precis Oncol. 2024. PMID: 39637338 Free PMC article.
91 results